Zymeworks BC Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-11-22: Form 8-K; Period of report 2019-11-22; Description 8.01 Other Events; Details 8.01.
- 2019-11-18: Form 8-K; Period of report 2019-11-18; Description 8.01 Other Events; Details 8.01.
- 2019-11-06: Form 8-K; Period of report 2019-11-05; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2019-11-05: Form 8-K; Period of report 2019-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-11-22 | 8-K | 2019-11-22 | 8.01 Other Events | 8.01 On November 22, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release announcing updated Phase 1 data for single agent ZW25 in heavily pretreated patients with HER2-expressing solid tumors in a mini oral presentation by Dr. Do-Youn Oh, study investigator and Professor at Seoul National University, at the ESMO Asia 2019 Congress, taking place November 22—24 in Singapore. | d836726d8k.htm |
| 2019-11-18 | 8-K | 2019-11-18 | 8.01 Other Events | 8.01 On November 18, 2019, Zymeworks Inc. issued a press release announcing the selection of an abstract highlighting updated single agent data from the Phase 1 clinical trial evaluating the HER2-targeted bispecific antibody, ZW25, in patients with HER2-expressing solid tumors for a mini oral presentation at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore. | d834259d8k.htm |
| 2019-11-06 | 8-K | 2019-11-05 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On November 5, 2019, Zymeworks Inc. (the “Company”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) under which it may offer and sell its common shares having aggregate sales proceeds of up to US$75.0 million from time to time through Jefferies as its sales agent. 8.01 On November 5, 2019, the Company issued a press release regarding the filing of the Registration Statement and the matters described in Item 1.01 above. | d828966d8k.htm |
| 2019-11-05 | 8-K | 2019-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2019, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2019. | d820728d8k.htm |
| 2019-11-04 | 8-K | 2019-11-04 | 8.01 Other Events | 8.01 On November 4, 2019, Zymeworks Inc. issued a press release announcing that management will present at the upcoming Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York, NY. | d827964d8k.htm |
| 2019-10-28 | 8-K | 2019-10-28 | 8.01 Other Events | 8.01 On October 28, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release announcing the first data from its Phase 1 study evaluating novel bispecific antibody ZW25 in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma (GEA) in a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 26 - 30 in Boston. | d787733d8k.htm |
| 2019-10-16 | 8-K | 2019-10-16 | 8.01 Other Events | 8.01 On October 16, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release announcing the appointment of Kathryn O’Driscoll to Zymeworks’ executive team as Chief People Officer (CPO). | d796326d8k.htm |
| 2019-09-30 | 8-K | 2019-09-28 | 8.01 Other Events | 8.01 On September 28, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release announcing updated data from the ongoing multi-center Phase 1 clinical trial evaluating ZW25 in patients with HER2-expressing solid tumors, including biliary tract cancer (BTC), colorectal cancer (CRC), gynecological cancers, and gastroesophageal adenocarcinoma (GEA), in a poster discussion presentation at the ESMO 2019 Congress, taking place September 27 – October 1 in Barcelona, Spain. | d809269d8k.htm |
| 2019-09-20 | 8-K/A | 2019-09-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On September 16, 2019, the Board appointed Mr. Cox and Dr. Mahoney to serve as members of the Audit Committee, Dr. Mahoney to serve as a member of the Compensation Committee and Mr. Cox to serve as a member of the Nominating and Corporate Governance Committee, each appointment effective on that date. | d807802d8ka.htm |
| 2019-09-18 | 8-K | 2019-09-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 (b) Effective September 16, 2019, Nick Bedford retired from his position as a member and Chair of the board of directors (the “Board of Directors”) of Zymeworks Inc. (“Zymeworks” or the “Company”). 8.01 On September 17, 2019, Zymeworks announced its strategic decision to voluntarily delist its common shares from the Toronto Stock Exchange (TSX) in Canada (the “TSX Delisting”). | d783075d8k.htm |
| 2019-08-28 | 8-K | 2019-08-28 | 8.01 Other Events | 8.01 • Wells Fargo Securities’ 14th Annual Healthcare Conference is scheduled for September 4-5, 2019 in Boston, MA. | d785255d8k.htm |
| 2019-08-02 | 8-K | 2019-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 On August 2, 2019, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2019. | d784520d8k.htm |
| 2019-07-16 | 8-K | 2019-07-16 | 8.01 Other Events | 8.01 On July 16, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that its global biopharma partner Celgene Corporation (“Celgene”) has selected a lead therapeutic candidate in oncology for further development and exercised its option to a commercial license under the companies’ 2014 Azymetric™ collaboration and licensing agreement, and that Zymeworks will receive a US$7.5 million payment as a result of Celgene’s exercise of this option. | d28056d8k.htm |
| 2019-06-25 | 8-K | 2019-06-24 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On June 18, 2019, Zymeworks issued a press release announcing the filing of a preliminary prospectus supplement in connection with an offering of the Company's common shares and, in lieu of common shares, to a certain investor, pre-funded warrants to purchase common shares (the "Offering"), which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com (the "Launch Press Release"). 8.01 On June 25, 2019, Zymeworks filed a material change report regarding the launch, pricing and closing of the Offering, as described in the Launch Press Release, the Pricing Press Release and the Closing Press Release with the Canadian securities regulatory authorities. | form8k.htm |
| 2019-06-20 | 8-K | 2019-06-18 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 On June 19, 2019, Zymeworks Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC as representative of the several underwriters named in Schedule II thereto (the “Underwriters”), relating to the issuance and sale of 5,555,556 of the Company’s common shares and, in lieu of common shares, to a certain investor, pre-funded warrants to purchase up to 4,166,690 common shares (together the “Offered Securities”). 7.01 On June 18, 2019, Zymeworks issued a press release announcing the filing of a preliminary prospectus supplement in connection with the Offering, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d663729d8k.htm |
| 2019-06-13 | 8-K | 2019-06-12 | 8.01 Other Events | 8.01 On June 12, 2019, Zymeworks Inc. issued a press release announcing that management will present at the upcoming Raymond James Life Sciences and MedTech Conference taking place June 18-19, 2019 in New York, NY. | d756698d8k.htm |
| 2019-06-05 | 8-K | 2019-06-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 (d) On June 3, 2019, Troy Cox and Susan Mahony were appointed to the board of directors (the “Board”) of Zymeworks Inc. (the “Company”). 8.01 On June 4, 2019, the Company issued a press release announcing the appointments described above, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d55229d8k.htm |
| 2019-05-30 | 8-K | 2019-05-29 | 8.01 Other Events | 8.01 On May 29, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW25, a novel Azymetric™ bispecific antibody, for the first-line treatment of patients with HER2overexpressing gastroesophageal adenocarcinoma in combination with standard of care chemotherapy. | d94001d8k.htm |
| 2019-05-29 | 8-K | 2019-05-29 | 8.01 Other Events | 8.01 On May 29, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that it has earned a milestone payment from Merck (known as MSD outside the US and Canada) achieved under the companies’ 2014 research and license agreement. | d726442d8k.htm |
| 2019-05-28 | 8-K | 2019-05-28 | 8.01 Other Events | 8.01 On May 28, 2019, Zymeworks Inc. issued a press release announcing that management will present at the upcoming Jefferies 2019 Global Healthcare Conference taking place June 4-7, 2019 in New York, NY. | d728937d8k.htm |
| 2019-05-24 | 8-K | 2019-05-23 | 8.01 Other Events | 8.01 On May 23, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release announcing that it will host a webcast and conference call on Wednesday, May 29, 2019 at 8:30am ET (5:30am PT) to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships. | d756505d8k.htm |
| 2019-05-17 | 8-K | 2019-05-15 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On May 15, 2019, Zymeworks Inc. (“Zymeworks”) and GlaxoSmithKline Intellectual Property Development Limited (“GSK”), entered into an amendment (the “GSK Amendment”) to the Platform Technology Transfer and License Agreement, dated April 21, 2016 (the “Licensing and Collaboration Agreement”). 8.01 (“SEDAR”) at www.sedar.com. | form8k.htm |
| 2019-05-15 | 8-K | 2019-05-13 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On May 13, 2019, Zymeworks Inc. (“Zymeworks”) entered into a license agreement (the “Agreement”) with Iconic Therapeutics, Inc. (“Iconic”) pursuant to which the companies will collaborate to research, develop and commercialize antibody-drug conjugate products. 8.01 On May 14, 2019, Zymeworks issued a press release announcing the Agreement, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | form8k.htm |
| 2019-05-03 | 8-K | 2019-05-02 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 On May 2, 2019, Zymeworks Inc. (“Zymeworks”), held its 2019 annual meeting of shareholders (the “Annual Meeting”). 8.01 On May 3, 2019, Zymeworks issued a press release announcing the voting results of its Annual Meeting, which was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. | d740982d8k.htm |
| 2019-05-02 | 8-K | 2019-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2019, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2019. | d739573d8k.htm |
| 2019-04-30 | 8-K | 2019-04-30 | 8.01 Other Events | 8.01 On April 30, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release reporting that it has expanded its leadership team with the hiring of three new vice presidents to support its expanded global clinical development: Mark Hollywood, Senior Vice President, Technical and Manufacturing Operations; Neil Josephson, M.D., Vice President, Clinical Research; and Bruce Hart, Ph.D., Vice President, Regulatory Affairs. | d733073d8k.htm |
| 2019-04-25 | 8-K | 2019-04-25 | 8.01 Other Events | 8.01 On April 25, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release reporting that Daiichi Sankyo Company, Limited (“Daiichi”) had exercised its option for a commercial license to a proprietary immuno-oncology bispecific built on Zymeworks’ Azymetric™ and EFECT™ platforms. | 8k.htm |
| 2019-04-23 | 8-K | 2019-04-23 | 8.01 Other Events | 8.01 On April 23, 2019, Zymeworks Inc. announced that management will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference taking place April 30-May 1, 2019 in Toronto, Canada. | d722636d8k.htm |
| 2019-04-15 | 8-K | 2019-04-15 | 8.01 Other Events | 8.01 On April 15, 2019, Zymeworks Inc. (the “Company”) announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas. | d726496d8k.htm |
| 2019-03-06 | 8-K | 2019-03-06 | 2.02 Results of Operations and Financial Condition | 2.02 On March 6, 2019, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2018. | d718184d8k.htm |
| 2019-03-05 | 8-K | 2019-03-05 | 8.01 Other Events | 8.01 On March 5, 2019, Zymeworks Inc. (the “Company”) announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 12-14, 2019 in Miami Beach, Florida. | form8k.htm |
| 2019-01-31 | 8-K | 2019-01-25 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On January 25, 2019, Zymeworks, Inc. (the “Company”), entered into an Indenture of Lease (the “Lease”) with 5th & Main Partnership (the “Landlord”) to lease approximately 57,180 rentable square feet of office and laboratory space on the sixth, seventh and eighth floors (the “Premises”) and 2,780 rentable square feet of storage space (the “Storage Rooms”) in the building to be constructed at 114 East 4th Avenue, Vancouver, B.C., Canada (the “Building”). 2.03 The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference. | form8-k.htm |
| 2019-01-17 | 8-K | 2019-01-17 | 8.01 Other Events | 8.01 On January 17, 2019, Zymeworks Inc. issued a press release reporting the achievement of a new development milestone in its collaboration with Eli Lilly and Company. | 8k.htm |
| 2019-01-07 | 8-K | 2019-01-06 | 8.01 Other Events | 8.01 On January 6, 2019, Zymeworks Inc. issued a press release reviewing its key 2018 accomplishments and outlining its priorities for 2019. | form8-k.htm |